A 38-year-old man from rural Maharashtra presents with a 3-month history of productive cough, fever, and night sweats. Chest X-ray shows cavitary lesions in the right upper lobe. Sputum smear microscopy (Ziehl-Neelsen stain) is positive for acid-fast bacilli. He has no prior TB treatment. What is the most appropriate next step in management?

Explanation

## Clinical Context This is a case of **microbiologically-confirmed pulmonary TB** (sputum smear-positive) with cavitary disease in a treatment-naïve patient. ## Management Principle **Key Point:** In India (NTEP guidelines), once TB is confirmed by sputum microscopy or culture, anti-TB therapy must be initiated **immediately** without waiting for drug susceptibility testing (DST) results, unless there is a specific risk factor for drug resistance (prior TB treatment, contact with MDR-TB, etc.). ## Why Immediate Therapy? 1. **Infectivity risk:** Sputum-positive patients remain infectious and pose public health risk. 2. **Clinical deterioration:** Delaying therapy in symptomatic cavitary TB increases morbidity and mortality. 3. **Standard protocol:** NTEP and WHO guidelines recommend starting standard first-line therapy (HRZE) in new cases without awaiting DST. ## Dosing Schedule - **Intensive phase:** HRZE for 2 months - **Continuation phase:** HR (isoniazid + rifampicin) for 4 months - Total duration: 6 months for new pulmonary TB **High-Yield:** The phrase "no prior TB treatment" and "sputum smear-positive" are red flags that say **START THERAPY NOW**. DST is done in parallel (for surveillance and to guide therapy if resistance is detected later), not as a prerequisite. ## Role of Imaging Chest X-ray has already been done and confirms the diagnosis. CT is not needed for initial management decision in straightforward cavitary TB.